Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220160 | 1.00 | GSR (0.39) | GSRPTGS2PTGS1ALDH1A1 | |
| SCHEMBL221241 | 1.00 | GSR (0.39) | GSRPTGS2PTGS1ALDH1A1 | |
| Water SCHEMBL23421028 | 0.98 | GSR (0.38) | GSRPTGS2PTGS1ALDH1A1 | |
| Ethylene SCHEMBL6857284 | 0.96 | GSR (0.37) | GSRPTGS2PTGS1ALDH1A1 | |
| SCHEMBL7611153 | 0.94 | GSR (0.36) | GSRPTGS2PTGS1ALDH1A1 | |
| Ether SCHEMBL23111929 | 0.89 | PTGS2 (0.36) | GSRPTGS2PTGS1 | |
| Nitroglycerin SCHEMBL15421 | 0.86 | PTGS2 (0.40) | GSRPTGS2PTGS1ALDH1A1 | |
| Nitroglycerin SCHEMBL920644 | 0.86 | PTGS2 (0.40) | GSRPTGS2PTGS1ALDH1A1 | |
| Nitroglycerin SCHEMBL9348180 | 0.86 | PTGS2 (0.38) | GSRPTGS2PTGS1ALDH1A1 | |
| Nitroglycerin SCHEMBL28125007 | 0.85 | PTGS2 (0.42) | GSRPTGS2PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | ALTI LLC (US) | 2026-04-23 | — | — | US | claimed |
| US-12517047-B2 | Transport and detection of explosive samples | ALTI LLC (US) | 2026-01-06 | — | — | US | claimed |
| US-20250270178-A1 | METHODS OF PRODUCING A NITRATE ESTER | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2025-08-28 | — | — | US | claimed |
| US-20250237601-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES | ALTI LLC | 2025-07-24 | — | — | US | claimed |
| CN-117650279-A | Nonaqueous electrolyte and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-03-05 | — | — | CN | claimed |
| US-20230355500-A1 | TOPICAL COMPOSITION | LILIGER LTD (IL) | 2023-11-09 | — | — | US | claimed |
| US-20230183198-A1 | METHODS OF PRODUCING GLYCIDYL NITRATE AND RELATED SYSTEMS | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2023-06-15 | — | — | US | claimed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-113181268-A | Combined composition for resisting myocardial infarction | 李开桥 | 2021-07-30 | — | — | CN | claimed |
| WO-2021073535-A1 | METHOD FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH ADMINISTRATION OF VEGFR AND/OR VEGF INHIBITOR | 上海岸阔医药科技有限公司 | 2021-04-22 | — | — | WO | claimed |
| JP-3211892-B2 | — | — | 2001-09-25 | — | — | JP | claimed |
| WO-2001002336-A1 | PROCESS FOR THE PRODUCTION OF GLYCEROL DINITRATES | QINETIQ LIMITED (GB) | 2001-01-11 | — | — | WO | claimed |
| EP-1051972-A1 | Nitric oxide donor composition and method for treatment of anal disorders | Cellegy Pharmaceuticals, Inc (US) | 2000-11-15 | — | — | EP | claimed |
| WO-2000051978-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METODS OF USE | NITROMED, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| EP-0719145-B1 | NITRIC OXIDE DONOR COMPOSITION FOR TREATMENT OF ANAL DISORDERS | CELLEGY PHARMA INC (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0719145-A4 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | CELLEGY PHARMA INC (US) | 1999-01-20 | — | — | EP | claimed |
| US-5693676-A | USING NITROGLYCERIN TO TREAT ANAL FISSURES OR ULCERS, HEMORRHOIDS, LEVATOR SPASMS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1997-12-02 | — | — | US | claimed |
| EP-0719145-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1996-07-03 | — | — | EP | claimed |
| WO-1995032715-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1995-12-07 | — | — | WO | claimed |
| US-3977922-A | NITRO COMPOUNDS IN THERMOSETTING RESINS | NIPPON OILS AND FATS COMPANY LIMITED (JA) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183198-A1 | METHODS OF PRODUCING GLYCIDYL NITRATE AND RELATED SYSTEMS | GMPS, PTGIS, GK | GSR 62/4885PTGS2 12/4885PTGS1 17/4885 |
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | TES, TNPO1, SLC2A1 | GSR 202/4885PTGS2 394/4885PTGS1 370/4885 |
| US-20250270178-A1 | METHODS OF PRODUCING A NITRATE ESTER | NOS2, NOS3, NOS1 | GSR 94/4885PTGS2 359/4885PTGS1 194/4885 |
| US-20230355500-A1 | TOPICAL COMPOSITION | NOS1, NOS3, NOS2 | GSR 636/4885PTGS2 198/4885PTGS1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.